Research
Hormonal
Dual and triple agonists show effectiveness on validated surrogate NAFLD biomarkers.
There is potential for dual and triple agonists to be effective in treating NAFLD, warranting further investigation.
StrongSupportsmedium confidence
Both dual and triple agonists are promising, based on animal, pharmacokinetic and proof-of concept studies, showing effectiveness... on a few validated surrogate NAFLD biomarkers.
Why this rating
The claim is based on a review of various studies.
Source
Looking ahead to potential incretin combination therapies for nonalcoholic steatohepatitis in patients with diabetes
Lucia Brodosi et al. · Expert Opinion on Pharmacotherapy · 2023
DOI 10.1080/14656566.2023.2208746
reviewCited 7×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →